Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract

Zunhao Zhang,1,* Bo Tian,1,* Hui Xu,1 He Huang,1 Xianwei Liang,1 Changwen Bo,1 Yunfei Bian,1 Ming Wei,2 Zhitao Zhao3 1Department of Oncology, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of General Surgery, Hebei Key La...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhang Z, Tian B, Xu H, Huang H, Liang X, Bo C, Bian Y, Wei M, Zhao Z
Format: Article
Language:English
Published: Dove Medical Press 2025-08-01
Series:Cancer Management and Research
Subjects:
Online Access:https://www.dovepress.com/investigating-the-efficacy-and-safety-of-the-cyberknife-system-for-tre-peer-reviewed-fulltext-article-CMAR
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849239175507738624
author Zhang Z
Tian B
Xu H
Huang H
Liang X
Bo C
Bian Y
Wei M
Zhao Z
author_facet Zhang Z
Tian B
Xu H
Huang H
Liang X
Bo C
Bian Y
Wei M
Zhao Z
author_sort Zhang Z
collection DOAJ
description Zunhao Zhang,1,* Bo Tian,1,* Hui Xu,1 He Huang,1 Xianwei Liang,1 Changwen Bo,1 Yunfei Bian,1 Ming Wei,2 Zhitao Zhao3 1Department of Oncology, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People’s Republic of China; 3Intensive Care Unit, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ming Wei, Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People’s Republic of China, Tel +86-18633888663, Email 314926509@qq.com Zhitao Zhao, Intensive Care Unit, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China, Tel +86-18032808723, Email tsld60@163.comObjective: This study aimed to investigate the effectiveness and safety of CyberKnife in the treatment of primary pancreatic cancer with metastases to the gastrointestinal tract (ie, primary pancreatic adenocarcinoma metastasizing to gastrointestinal organs).Methods: A total of 106 patients with primary pancreatic cancer and metastases to the gastrointestinal tract admitted to our hospital received CyberKnife treatment. Recent treatment efficacy (assessed at 3 months post-treatment), median survival period, pain levels, and adverse reactions were analyzed.Results: Among the 106 patients, 17 cases (16.04%) achieved complete response (CR), 61 cases (57.55%) achieved partial response (PR), 20 cases (18.87%) had stable disease (SD), and 8 cases (7.55%) had progressive disease (PD), resulting in an objective response rate (ORR) of 73.59% and an overall disease control rate (DCR) of 92.45% (98 cases). The one-year and two-year overall survival (OS) rates were 74.53% and 55.66%, respectively, while the local control (LC) rates were 92.45% and 87.74%, respectively. The median OS was 8.17 months (range: 1– 25 months). Mean pain scores (Visual Analog Scale) decreased significantly from 5.38± 1.37 at baseline to 2.01± 0.35 post-treatment (p< 0.001). Abdominal and lumbar pain significantly improved after 2 weeks of radiotherapy. Among the 68 patients with baseline pain who experienced relief, analgesic medication was discontinued in 25 (36.8%) patients, reduced by ≥ 50% in 18 patients (26.5%), and by approximately 25% in 5 patients (7.3%). Quality of life improved in 27 patients, remained stable in 52, and declined in 27, yielding an overall improvement or stabilization rate of 74.53% (79 cases).Conclusion: CyberKnife SBRT appears to be a promising treatment modality for managing primary pancreatic cancer with metastases to the gastrointestinal tract, with minimal adverse reactions.Keywords: CyberKnife, pancreatic cancer, gastrointestinal metastases, stereotactic body radiotherapy, survival outcomes
format Article
id doaj-art-8b191673ec3a4347ae900cb962328ec6
institution Kabale University
issn 1179-1322
language English
publishDate 2025-08-01
publisher Dove Medical Press
record_format Article
series Cancer Management and Research
spelling doaj-art-8b191673ec3a4347ae900cb962328ec62025-08-20T04:01:09ZengDove Medical PressCancer Management and Research1179-13222025-08-01Volume 17Issue 115891598105568Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal TractZhang ZTian BXu HHuang HLiang XBo CBian YWei MZhao ZZunhao Zhang,1,* Bo Tian,1,* Hui Xu,1 He Huang,1 Xianwei Liang,1 Changwen Bo,1 Yunfei Bian,1 Ming Wei,2 Zhitao Zhao3 1Department of Oncology, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People’s Republic of China; 3Intensive Care Unit, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ming Wei, Department of General Surgery, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, People’s Republic of China, Tel +86-18633888663, Email 314926509@qq.com Zhitao Zhao, Intensive Care Unit, The First Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China, Tel +86-18032808723, Email tsld60@163.comObjective: This study aimed to investigate the effectiveness and safety of CyberKnife in the treatment of primary pancreatic cancer with metastases to the gastrointestinal tract (ie, primary pancreatic adenocarcinoma metastasizing to gastrointestinal organs).Methods: A total of 106 patients with primary pancreatic cancer and metastases to the gastrointestinal tract admitted to our hospital received CyberKnife treatment. Recent treatment efficacy (assessed at 3 months post-treatment), median survival period, pain levels, and adverse reactions were analyzed.Results: Among the 106 patients, 17 cases (16.04%) achieved complete response (CR), 61 cases (57.55%) achieved partial response (PR), 20 cases (18.87%) had stable disease (SD), and 8 cases (7.55%) had progressive disease (PD), resulting in an objective response rate (ORR) of 73.59% and an overall disease control rate (DCR) of 92.45% (98 cases). The one-year and two-year overall survival (OS) rates were 74.53% and 55.66%, respectively, while the local control (LC) rates were 92.45% and 87.74%, respectively. The median OS was 8.17 months (range: 1– 25 months). Mean pain scores (Visual Analog Scale) decreased significantly from 5.38± 1.37 at baseline to 2.01± 0.35 post-treatment (p< 0.001). Abdominal and lumbar pain significantly improved after 2 weeks of radiotherapy. Among the 68 patients with baseline pain who experienced relief, analgesic medication was discontinued in 25 (36.8%) patients, reduced by ≥ 50% in 18 patients (26.5%), and by approximately 25% in 5 patients (7.3%). Quality of life improved in 27 patients, remained stable in 52, and declined in 27, yielding an overall improvement or stabilization rate of 74.53% (79 cases).Conclusion: CyberKnife SBRT appears to be a promising treatment modality for managing primary pancreatic cancer with metastases to the gastrointestinal tract, with minimal adverse reactions.Keywords: CyberKnife, pancreatic cancer, gastrointestinal metastases, stereotactic body radiotherapy, survival outcomeshttps://www.dovepress.com/investigating-the-efficacy-and-safety-of-the-cyberknife-system-for-tre-peer-reviewed-fulltext-article-CMARCyberKnifePancreatic cancerGastrointestinal metastasesStereotactic body radiotherapySurvival outcomes
spellingShingle Zhang Z
Tian B
Xu H
Huang H
Liang X
Bo C
Bian Y
Wei M
Zhao Z
Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract
Cancer Management and Research
CyberKnife
Pancreatic cancer
Gastrointestinal metastases
Stereotactic body radiotherapy
Survival outcomes
title Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract
title_full Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract
title_fullStr Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract
title_full_unstemmed Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract
title_short Investigating the Efficacy and Safety of the CyberKnife System for Treating Primary Pancreatic Cancer with Metastases to the Gastrointestinal Tract
title_sort investigating the efficacy and safety of the cyberknife system for treating primary pancreatic cancer with metastases to the gastrointestinal tract
topic CyberKnife
Pancreatic cancer
Gastrointestinal metastases
Stereotactic body radiotherapy
Survival outcomes
url https://www.dovepress.com/investigating-the-efficacy-and-safety-of-the-cyberknife-system-for-tre-peer-reviewed-fulltext-article-CMAR
work_keys_str_mv AT zhangz investigatingtheefficacyandsafetyofthecyberknifesystemfortreatingprimarypancreaticcancerwithmetastasestothegastrointestinaltract
AT tianb investigatingtheefficacyandsafetyofthecyberknifesystemfortreatingprimarypancreaticcancerwithmetastasestothegastrointestinaltract
AT xuh investigatingtheefficacyandsafetyofthecyberknifesystemfortreatingprimarypancreaticcancerwithmetastasestothegastrointestinaltract
AT huangh investigatingtheefficacyandsafetyofthecyberknifesystemfortreatingprimarypancreaticcancerwithmetastasestothegastrointestinaltract
AT liangx investigatingtheefficacyandsafetyofthecyberknifesystemfortreatingprimarypancreaticcancerwithmetastasestothegastrointestinaltract
AT boc investigatingtheefficacyandsafetyofthecyberknifesystemfortreatingprimarypancreaticcancerwithmetastasestothegastrointestinaltract
AT biany investigatingtheefficacyandsafetyofthecyberknifesystemfortreatingprimarypancreaticcancerwithmetastasestothegastrointestinaltract
AT weim investigatingtheefficacyandsafetyofthecyberknifesystemfortreatingprimarypancreaticcancerwithmetastasestothegastrointestinaltract
AT zhaoz investigatingtheefficacyandsafetyofthecyberknifesystemfortreatingprimarypancreaticcancerwithmetastasestothegastrointestinaltract